Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
EW 
Edwards Lifesciences Corp (EW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: EW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
32 Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $87.14
1 Year Target Price $87.14
| 10 | Strong Buy |
| 4 | Buy |
| 17 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -5.23% | Avg. Invested days 48 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 42.82B USD | Price to earnings Ratio 30.51 | 1Y Target Price 87.14 |
Price to earnings Ratio 30.51 | 1Y Target Price 87.14 | ||
Volume (30-day avg) 32 | Beta 1.05 | 52 Weeks Range 64.89 - 83.00 | Updated Date 10/15/2025 |
52 Weeks Range 64.89 - 83.00 | Updated Date 10/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.39 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 72.96% | Operating Margin (TTM) 28.12% |
Management Effectiveness
Return on Assets (TTM) 8.42% | Return on Equity (TTM) 15.53% |
Valuation
Trailing PE 30.51 | Forward PE 27.86 | Enterprise Value 41641615000 | Price to Sales(TTM) 7.53 |
Enterprise Value 41641615000 | Price to Sales(TTM) 7.53 | ||
Enterprise Value to Revenue 7.32 | Enterprise Value to EBITDA 22.78 | Shares Outstanding 587100000 | Shares Floating 581099838 |
Shares Outstanding 587100000 | Shares Floating 581099838 | ||
Percent Insiders 0.91 | Percent Institutions 88.11 |
Upturn AI SWOT
Edwards Lifesciences Corp
Company Overview
History and Background
Edwards Lifesciences was founded in 1958 by Miles "Lowell" Edwards and Dr. Albert Starr, pioneering the first commercially available heart valve. Initially a division of American Hospital Supply Corporation, it became an independent company in 2000. Over time, Edwards has focused on advancing heart valve technologies and critical care monitoring.
Core Business Areas
- Transcatheter Aortic Valve Replacement (TAVR): This segment focuses on minimally invasive heart valve replacement technology, addressing aortic stenosis. It's Edwards' largest revenue generator.
- Transcatheter Mitral and Tricuspid Therapies (TMTT): This segment focuses on developing transcatheter solutions for mitral and tricuspid valve diseases. It is a growing area within Edwards Lifesciences.
- Surgical Structural Heart: This segment offers surgical heart valve replacement and repair products.
- Critical Care: This segment provides hemodynamic monitoring systems to assess a patient's cardiovascular function during critical illness and surgery.
Leadership and Structure
The company is led by CEO Bernard Zovighian. Edwards Lifesciences operates with a global organizational structure, divided by product segments and geographic regions.
Top Products and Market Share
Key Offerings
- SAPIEN TAVR Valves: The SAPIEN family of transcatheter aortic heart valves is Edwards' flagship product. This product has a significant market share within the TAVR market. Competitors include Medtronic (MDT), Abbott (ABT), and Boston Scientific (BSX).
- Surgical Heart Valves: Edwards offers a range of surgical heart valves, including PERIMOUNT and INSPIRIS valves. Competitors are similar to TAVR (Medtronic, Abbott, and Boston Scientific).
- HemoSphere Advanced Monitoring Platform: This platform provides real-time hemodynamic data to guide clinical decision-making in critical care settings. Competitors include ICU Medical (ICUI) and GE HealthCare (GEHC).
Market Dynamics
Industry Overview
The cardiovascular device market is large and growing, driven by an aging population, increasing prevalence of heart disease, and technological advancements in minimally invasive procedures.
Positioning
Edwards Lifesciences is a leader in the structural heart disease market, particularly in TAVR. Its competitive advantages include strong brand recognition, extensive clinical data supporting its products, and a focus on innovation.
Total Addressable Market (TAM)
The global structural heart market is estimated at $15+ billion and growing. Edwards Lifesciences is well-positioned to capture a significant portion of this TAM through its leadership in TAVR and expansion into TMTT.
Upturn SWOT Analysis
Strengths
- Market leadership in TAVR
- Strong brand reputation
- Extensive clinical data supporting products
- Focus on innovation
- Global presence
Weaknesses
- High dependence on TAVR revenue
- Exposure to regulatory risks
- Competition in established markets
Opportunities
- Expansion into TMTT market
- Growth in emerging markets
- Development of new technologies
- Partnerships and acquisitions
Threats
- Increasing competition
- Pricing pressures
- Technological obsolescence
- Economic downturn
Competitors and Market Share
Key Competitors
- MDT
- ABT
- BSX
Competitive Landscape
Edwards Lifesciences has a strong competitive position in the structural heart market, particularly in TAVR. Its advantages include its established brand, extensive clinical data, and focus on innovation. Competition is increasing, particularly in TMTT.
Major Acquisitions
Valcare Medical
- Year: 2022
- Acquisition Price (USD millions): 50
- Strategic Rationale: Strengthen Edwards' portfolio in the transcatheter tricuspid valve repair space.
Growth Trajectory and Initiatives
Historical Growth: Edwards Lifesciences has experienced strong revenue growth over the past decade, driven by the adoption of TAVR technology.
Future Projections: Analysts project continued revenue growth for Edwards Lifesciences, driven by expansion into new markets and continued innovation. TMTT represents a significant growth opportunity.
Recent Initiatives: Recent initiatives include investments in R&D for TMTT, expansion of manufacturing capacity, and strategic acquisitions.
Summary
Edwards Lifesciences is a strong company with a leading position in the structural heart market, particularly in TAVR. The company has a solid financial performance and a focus on innovation. While competition is increasing, the opportunity in the TMTT market presents a significant growth opportunity. It should continue its investment in R&D and strategic aquisitions to maintain its strong leadership position and to diversify its revenue streams.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10K, 10Q)
- Company Investor Relations
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share estimates are approximations and can vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Edwards Lifesciences Corp
Exchange NYSE | Headquaters Irvine, CA, United States | ||
IPO Launch date 2000-03-27 | CEO & Director Mr. Bernard J. Zovighian | ||
Sector Healthcare | Industry Medical Devices | Full time employees 15800 | Website https://www.edwards.com |
Full time employees 15800 | Website https://www.edwards.com | ||
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.